The Role At Treewalk, you'll own the entire public-company reporting cycle: fast closes, MD&A storytelling, IFRS/US GAAP judgment calls, and scalable system design. You'll own end-to-end financial disclosure for a portfolio of high growth clients in life sciences, including pharmaceuticals, therapeutics, and other applications of biosciences and biotechnology. Many engagements will tap you as a de-facto fractional CFO, guiding strategy as well as disclosure; others will lean on you as the go-to technical expert. Either way, every file is yours to run.
Deadlines are real; overtime isn't a lifestyle. We staff sensibly, treat extra hours as the rare exception, and back that up with true schedule autonomy and remote flexibility-so your evenings stay yours.
If you've led pub-co audits at a small- to mid-size firm or managed reporting inside a listed issuer, and you're ready to trade 70-hour busy-season marathons for high-impact work, tangible ownership, and genuine balance, then we would love to hear from you.
How You'll Create Impact Day-to-Day- Own the story behind the numbers: Draft and polish quarterly and annual financial statements and MD&A that stand up to capital-markets scrutiny and tell each client's growth narrative from the science, to the milestones, and the financial commitments required to achieve the business objectives.
- Make R&D spend make sense: Advise clients on accounting for research and development costs, clinical and pre-clinical trial accruals, CRO/CDMO arrangements, and measuring burn rate against progress.
- Master the technical hurdles: Tackle complex issues such as licensing and collaboration agreements, milestone and royalty revenue, acquired IPR&D, government grants and funding, intangible assets and impairment, and package them into robust technical memos and disclosures.
- Untangle complex capital structures: Work through warrants, convertible instruments, derivative liabilities, royalty and streaming financings, unit offerings, debt/equity splits, and stock-based compensation.
- Run the engine of multi-entity groups: Build rock-solid consolidation and foreign-currency translation models that make complex structures look effortless.
- Turn data into insight: Deliver sharp balance sheet and P&L analyses, spotlighting trends and red-flag variances before anyone else sees them.
- Keep leadership laser-focused: Produce monthly variance reports against forecasts and annual plans, translating the findings into clear, action-ready recommendations, including cash runway and financing timing.
- Shape the roadmap: Guide annual budgets and rolling forecasts, aligning stakeholders around targets that push the business without breaking it.
- Step in as the "extra brain": Handle special-project bookkeeping or period-end close entries when clients need a fractional controller's precision and speed.
- Make audits painless: Design year-end audit plans, prep airtight support, and quarterback conversations with external auditors so CEOs and CFOs can sleep at night.
- Guard continuous disclosure: Stay ahead of regulatory changes, draft timely filings, and ensure nothing slips through the cracks on SEDAR+ or EDGAR.
- Build and grow the industry service line: Take ownership of the practice area and scale it, and develop the people who will run alongside you.
Result: clients see you as the calm, expert voice who keeps them compliant and strategic, while you build Treewalk's Biotechnology and Life Sciences service line without the grind of traditional public practice.RequirementsOur ideal candidate...- CPA designation required.
- Significant public company audit and/or financial reporting experience, serving or working within pre-revenue or early-commercial biotechnology, pharmaceutical, or other life sciences reporting issuers listed in Canada and/or the US.
- Hands-on technical depth in life sciences accounting and fluency in the drug and product development lifecycle.
- After the base experience requirements are met, we hire first and foremost for strong analytical and problem-solving skills.
BenefitsAnnual Salary: $125,000
